8.46
-0.12(-1.40%)
Currency In USD
| Previous Close | 8.58 |
| Open | 8.49 |
| Day High | 8.52 |
| Day Low | 8.24 |
| 52-Week High | 12.49 |
| 52-Week Low | 5.41 |
| Volume | 1.56M |
| Average Volume | 1.51M |
| Market Cap | 736.17M |
| PE | -3.41 |
| EPS | -2.48 |
| Moving Average 50 Days | 9.5 |
| Moving Average 200 Days | 8.23 |
| Change | -0.12 |
If you invested $1000 in Kura Oncology, Inc. (KURA) 10 years ago, it would be worth $1,796.18 as of February 21, 2026 at a share price of $8.46. Whereas If you bought $1000 worth of Kura Oncology, Inc. (KURA) shares 5 years ago, it would be worth $256.05 as of February 21, 2026 at a share price of $8.46.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Kura Oncology Highlights Recent Accomplishments, Preliminary KOMZIFTI Revenue and Anticipated 2026 Milestones
GlobeNewswire Inc.
Jan 11, 2026 10:00 PM GMT
– Launched KOMZIFTI™ (ziftomenib), first and only once-daily, oral menin inhibitor approved for adults with R/R NPM1-mutated AML – – $2.1 million KOMZIFTI net product revenue for the period from first commercial sale on November 21, 2025, through De
Kura Oncology and Kyowa Kirin Report Combination Data for KOMZIFTI™ (Ziftomenib) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory AML
GlobeNewswire Inc.
Dec 08, 2025 3:30 PM GMT
– 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS – Median duration of complete response and overall survival not yet reached in newly diagnosed N
Kura Oncology to Host Virtual Investor Event to Discuss Data Presented at ASH 2025 on Triplet Combination of Ziftomenib (KOMZIFTI®) with Venetoclax and Azacitidine in Newly Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia
GlobeNewswire Inc.
Dec 03, 2025 1:32 PM GMT
Event Scheduled for December 8, 2025 at 12:30 PM ETSAN DIEGO, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, t